FOX CHASE CHEMICAL DIVERSITY CENTER INC.
- DOYLESTOWN, PA 18902-8400
- Corporate Entity (Not Tax Exempt)
- SAM expiring
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $0
- Awards on record
- 0
- Contract vehicles
- 0
- Verified credentials
- 0
SAM.gov registration expires in 56 days
FOX CHASE CHEMICAL DIVERSITY CENTER INC.’s registration expires on Jan 8, 2027. Renewal can take weeks; confirm it stays active through proposal submission and award.
View on SAM.gov (opens in a new tab)Learn more about SAM registration and the UEI
About FOX CHASE CHEMICAL DIVERSITY CENTER INC.
- Headquarters
- DOYLESTOWN, PA 18902-8400
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIV6EQM9ABEM89
- CAGE590A6
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
No federal prime awards on record
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 37 awards
- Total awarded
- $40,525,779
- By phase
- STTR Phase I: 16
- SBIR Phase I: 8
- SBIR Phase II: 8
- STTR Phase II: 5
- By agency
- Department of Health and Human Services: 37
- Active projects
- 1 project
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 1 project
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2025: 1
- 2024: 1
- 2023: 1
- 2022: 3
- 2021: 2
- 2020: 4
- 2019: 2
- 2018: 4
- 2017: 4
- 2016: 3
- 2015: 4
- 2014: 3
- 2013: 3
- 2011: 1
- 2009: 1
Awards (most recent first)
Combinations of Oral Antibiotics to Treat Syphilis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2025 · $306,500
Solicitation PHS 2024-1 (2024) · Topic 134
Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum
STTR Phase II · Department of Health and Human Services (National Institutes of Health) · 2024 · $2,006,966
Aug 1, 2024 – Jul 31, 2027
- Active
- Ends Jul 2027
Solicitation PA22-178 (2022) · Topic 42 · Research partner: UNIVERSITY OF PENNSYLVANIA
Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2023 · $3,050,000
Apr 15, 2023 – Mar 31, 2026
Solicitation PA21-259 (2021) · Topic NIAID
Development of Host- Oriented Therapeutics Targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2022 · $598,928
Aug 22, 2022 – Jul 31, 2024
Solicitation PA21-262 (2021) · Topic NIAID · Research partner: UNIVERSITY OF PENNSYLVANIA
Development of FosA Inhibitors to Potentiate Fosfomycin Activity in Gram-Negative Pathogens
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2022 · $598,124
Aug 15, 2022 – Jun 30, 2024
Solicitation PA21-262 (2021) · Topic NIAID · Research partner: UNIVERSITY OF PITTSBURGH
Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis
STTR Phase II · Department of Health and Human Services (National Institutes of Health) · 2022 · $3,015,759
Jun 21, 2022 – May 31, 2025
Solicitation PA21-262 (2021) · Topic NIAID · Research partner: UNIVERSITY OF PENNSYLVANIA
Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2021 · $606,500
Apr 19, 2021 – Mar 31, 2023
Solicitation PA20-265 (2020) · Topic NIAID · Research partner: UNIVERSITY OF PENNSYLVANIA
Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses
STTR Phase II · Department of Health and Human Services (National Institutes of Health) · 2021 · $3,045,306
Apr 1, 2021 – Mar 31, 2024
Solicitation PA20-265 (2020) · Topic NIAID · Research partner: UNIVERSITY OF PENNSYLVANIA
Soft LXR Agonists for Idiopathic Pulmonary Fibrosis
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $306,500
Jul 20, 2020 – Jun 30, 2021
Solicitation PA19-270 (2019) · Topic NHLBI · Research partner: THOMAS JEFFERSON UNIVERSITY
Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $599,999
Jul 20, 2020 – Jun 30, 2022
Solicitation PA19-272 (2019) · Topic NIAID
PROTACS Against Nef as a Functional Cure for HIV Infection
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $597,797
Jul 1, 2020 – Jun 30, 2022
Solicitation PA19-270 (2019) · Topic NIAID · Research partner: FOX CHASE CHEMICAL DIVERSITY CENTER, INC
Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $309,102
May 1, 2020 – Apr 30, 2021
Solicitation PA18-575 (2018) · Topic NEI · Research partner: UNIVERSITY OF PENNSYLVANIA
Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2019 · $2,996,138
Sep 15, 2019 – Jun 30, 2022
Solicitation HL19-018 (2018) · Topic NHLBI
Discovering a Small Molecule that Targets the KSHV Processivity Factor for Treating Oral and Systemic Kaposi Sarcoma
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $300,000
May 1, 2019 – Apr 30, 2020
Solicitation PA18-575 (2018) · Topic NIDCR · Research partner: UNIVERSITY OF PENNSYLVANIA
Soft LXR Agonists for the Treatment of Idiopathic Pulmonary Fibrosis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $300,000
Sep 15, 2018 – Aug 31, 2019
Solicitation PA17-302 (2017) · Topic NHLBI
Riluzole Prodrugs for Melanoma and ALS
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2018 · $3,000,000
Sep 1, 2018 – Aug 31, 2021
Solicitation CA17-024 (2017) · Topic 102
Trigriluzole for the Treatment of Cocaine Addiction
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $300,002
Jul 1, 2018 – Jun 30, 2020
Solicitation PA17-303 (2017) · Topic NIDA · Research partner: TEMPLE UNIV OF THE COMMONWEALTH
Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $597,435
Jun 1, 2018 – May 31, 2021
Solicitation PA17-303 (2017) · Topic NIAID · Research partner: UNIVERSITY OF PENNSYLVANIA
PET Imaging Agents for the in vivo Detection of TDP-43
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2017 · $1,499,687
Sep 15, 2017 – Apr 30, 2020
- Direct to Phase II
Solicitation PAR14-088 (2014) · Topic NIA
Inhibitors of Hydrogen Sulfide Metabolism as a Novel Treatment for Heart Failure
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $300,000
Apr 24, 2017 – Apr 23, 2019
Solicitation PA16-303 (2016) · Topic NHLBI · Research partner: DREXEL UNIVERSITY
INHIBITORS OF THE PHD ZINC FINGER TO TREAT ANEMIA
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $300,000
Apr 1, 2017 – Mar 31, 2019
Solicitation PA16-302 (2016) · Topic NHLBI
DEVELOPMENT OF A NOVEL ANTIVIRAL TO TREAT AND PREVENT ACYCLOVIR RESISTANCE IN HUMAN OCULAR HERPES KERATITIS
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $299,999
Mar 1, 2017 – Feb 28, 2019
Solicitation PA15-270 (2015) · Topic N · Research partner: UNIVERSITY OF PENNSYLVANIA
Small Molecule Inhibitors of HIV Nef Virulence Factor for Treatment of HIV AIDS
STTR Phase II · Department of Health and Human Services (National Institutes of Health) · 2016 · $1,992,210
Sep 1, 2016 – Aug 31, 2019
Solicitation PA15-270 (2015) · Topic 100 · Research partner: UNIVERSITY OF PITTSBURGH
SMALL MOLECULE ANTAGONISTS OF PF FOR THE TREATMENT AND PREVENTION OF HIT
STTR Phase II · Department of Health and Human Services (National Institutes of Health) · 2016 · $1,942,140
Aug 15, 2016 – Jul 31, 2019
Solicitation PA14-072 (2014) · Topic NHLBI · Research partner: NEW YORK BLOOD CENTER
DEVELOPMENT OF TOPICAL ANTIVIRAL AGENTS FOR TREATING MOLLUSCUM CONTAGIOSUM
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2016 · $3,002,878
Apr 1, 2016 – Mar 31, 2020
- Direct to Phase II
Solicitation PAR14-088 (2014) · Topic NIAID
Showing the 25 most recent of 37 awards.
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 541714Research and Development in Biotechnology (except Nanobiotechnology)Primary
- 541715Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
SAM.gov does not report this entity as small under any listed NAICS code.
Socio-economic status
No socio-economic certifications reported in SAM.gov.
Product & service codes (PSC)
No PSC codes reported.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with FOX CHASE CHEMICAL DIVERSITY CENTER INC.?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.